These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17520582

  • 1. Clinical management of cutaneous toxicity of anti-EGFR agents.
    Monti M, Motta S.
    Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
    [Abstract] [Full Text] [Related]

  • 2. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A, Kroth J, Hauschild A, Dirschka T.
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J, Cencelj S.
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
    Tjin-A-ton ML, van Montfrans C, Koldenhof JJ, Sigurdsson V, Voest EE, Witteveen PO.
    Ned Tijdschr Geneeskd; 2007 Apr 28; 151(17):945-52. PubMed ID: 17520845
    [Abstract] [Full Text] [Related]

  • 9. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F.
    Dermatitis; 2012 Apr 28; 23(5):237-8. PubMed ID: 23010833
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A, Gutiérrez-Rivera A, López-Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, Arregui MA, Sarasqueta C, Lobo C, Tuneu A.
    Actas Dermosifiliogr; 2015 Apr 28; 106(6):483-92. PubMed ID: 25798804
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW.
    J Am Acad Dermatol; 2007 Feb 28; 56(2):317-26. PubMed ID: 17141360
    [Abstract] [Full Text] [Related]

  • 19. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A.
    J Am Acad Dermatol; 2015 Feb 28; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [Abstract] [Full Text] [Related]

  • 20. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
    Reimer G, Brudler O, Heinrich B, Bangerter M.
    MMW Fortschr Med; 2008 Dec 04; 150(49-50):37-8, 40. PubMed ID: 19133368
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.